Vise Technologies Inc. Invests $713,000 in Haleon PLC Sponsored ADR $HLN

Vise Technologies Inc. bought a new stake in Haleon PLC Sponsored ADR (NYSE:HLN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 68,758 shares of the company’s stock, valued at approximately $713,000.

A number of other large investors also recently modified their holdings of HLN. Brighton Jones LLC acquired a new position in Haleon during the fourth quarter worth $187,000. M&T Bank Corp lifted its stake in Haleon by 28.0% in the first quarter. M&T Bank Corp now owns 44,153 shares of the company’s stock valued at $455,000 after acquiring an additional 9,658 shares during the last quarter. Apollon Wealth Management LLC grew its position in shares of Haleon by 5.4% in the 1st quarter. Apollon Wealth Management LLC now owns 21,722 shares of the company’s stock valued at $224,000 after acquiring an additional 1,111 shares during the period. Cullen Frost Bankers Inc. increased its stake in shares of Haleon by 99.5% during the 1st quarter. Cullen Frost Bankers Inc. now owns 6,291 shares of the company’s stock worth $65,000 after purchasing an additional 3,137 shares during the last quarter. Finally, Bailard Inc. acquired a new position in shares of Haleon during the 1st quarter worth about $237,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of Haleon stock opened at $9.89 on Friday. The company’s 50 day moving average price is $9.28 and its two-hundred day moving average price is $9.92. The firm has a market capitalization of $44.02 billion, a P/E ratio of 25.35, a P/E/G ratio of 2.98 and a beta of 0.20. Haleon PLC Sponsored ADR has a fifty-two week low of $8.71 and a fifty-two week high of $11.42. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63.

Analysts Set New Price Targets

A number of research analysts recently weighed in on HLN shares. The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. Finally, Barclays lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.